Published in J Clin Microbiol on February 01, 1985
Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother (1988) 2.87
Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol (2002) 1.98
Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium. Antimicrob Agents Chemother (1988) 1.37
Evaluation of a radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1986) 1.22
Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.16
Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob Agents Chemother (1989) 1.15
Modified method for testing the quality of albumin-containing enrichments used in growth media for mycobacteria. J Clin Microbiol (1990) 0.95
Genotypic determination of Mycobacterium tuberculosis antibiotic resistance using a novel mutation detection method, the branch migration inhibition M. tuberculosis antibiotic resistance test. J Clin Microbiol (2000) 0.84
Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages. Antimicrob Agents Chemother (2015) 0.79
Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis (1977) 11.20
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (1981) 9.67
Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis (1974) 7.40
Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc (1954) 5.58
Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis (1967) 5.45
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Rapid drug-susceptibility testing of Mycobacterium tuberculosis. Am Rev Respir Dis (1981) 4.77
Rapid susceptibility testing of Mycobacterium tuberculosis by a radiometric technique. J Antimicrob Chemother (1982) 3.52
Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis (1967) 3.48
Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother (1981) 2.62
Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (1982) 2.44
Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother (1983) 2.25
A simple way of detecting pyrazinamide resistance. Tubercle (1972) 1.48
[Sensitivity of tubercle bacilli to pyrazinamide determined on the basis of their sensitivity to nicotinamide and their pyrazinamidase and nictinamidase activities]. Gruzlica (1974) 1.10
MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis (1998) 5.82
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med (1993) 5.22
Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med (1994) 4.74
Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am Rev Respir Dis (1987) 3.86
Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA (1993) 3.32
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.15
Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother (1988) 2.87
Tuberculosis symposium: emerging problems and promise. J Infect Dis (1993) 2.55
Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother (1986) 2.48
Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) (1985) 2.35
Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother (1973) 2.33
Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol (1993) 2.25
Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother (1985) 2.07
Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis (1991) 1.97
Immunologic diagnosis of tuberculosis: a review. Tuber Lung Dis (2000) 1.90
In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother (1988) 1.86
Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome. Antimicrob Agents Chemother (1986) 1.79
Immigrants and tuberculosis control. N Engl J Med (1995) 1.79
An unholy trinity--three negative sputum smears and release from tuberculosis isolation. Clin Infect Dis (1997) 1.64
Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis (1982) 1.63
Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis (1987) 1.62
Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. Antimicrob Agents Chemother (1985) 1.55
Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis (1990) 1.53
Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med (1992) 1.45
That's no lady. Chest (1996) 1.40
Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. Clin Infect Dis (1998) 1.39
Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med (1989) 1.35
Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis (1989) 1.28
Tuberculous empyema. Semin Respir Infect (1999) 1.22
Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis (1988) 1.17
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis (1995) 1.16
Health care workers and tuberculosis: the battle of a century. Int J Tuberc Lung Dis (1999) 1.15
Vertebral osteomyelitis due to infection with nontuberculous Mycobacterium species after blunt trauma to the back: 3 examples of the principle of locus minoris resistentiae. Clin Infect Dis (2001) 1.14
Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis (1987) 1.14
Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions. Antimicrob Agents Chemother (1988) 1.13
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. Am J Respir Crit Care Med (1997) 1.13
Tuberculosis in association with pregnancy. Am J Obstet Gynecol (1981) 1.13
Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis (1998) 1.10
Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis (1988) 1.10
Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle (1988) 1.10
Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp Clin Res (1987) 1.08
Disease due to Mycobacterium avium-intracellulare. Chest (1985) 1.06
Less is more: short-course preventive therapy of tuberculosis. Am Rev Respir Dis (1989) 1.05
Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis (1985) 1.05
Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan. Am Rev Respir Dis (1988) 1.04
Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on mycobacterium intracellulare. Am Rev Respir Dis (1985) 1.04
Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing. Clin Infect Dis (2000) 1.04
Syndrome and pancreatic disease, subcutaneous fat necrosis and polyserositis. Case report and review of literature. Am J Med (1975) 1.03
The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus Mycobacterium tuberculosis. Am Rev Respir Dis (1990) 1.03
Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages. Am Rev Respir Dis (1987) 1.02
Ten-year experience with artificial pneumoperitoneum for end-stage, drug-resistant pulmonary tuberculosis. Clin Infect Dis (1993) 1.02
Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis (1986) 1.01
Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest (1987) 1.01
The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis (1986) 1.00
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin Infect Dis (2001) 0.96
Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of Bacille Calmette-Guérin. Am J Med (1996) 0.96
The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Respir Dis (1992) 0.96
Tailoring a time-bomb. Inadvertent genetic engineering. Am Rev Respir Dis (1985) 0.96
Good news and not such good news. Int J Tuberc Lung Dis (1999) 0.93
Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis (1991) 0.93
American Thoracic Society. Medical Section of the American Lung Association. Guidelines for short-course tuberculosis chemotherapy. Am Rev Respir Dis (1980) 0.92
Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis (1996) 0.92
Containment of tuberculosis. Preventive therapy with isoniazid, and contact investigation. Chest (1979) 0.92
The increasing prevalence of resistance to antituberculosis chemotherapeutic agents: implications for global tuberculosis control. Curr Clin Top Infect Dis (1992) 0.91
Is standard chemotherapy adequate in tuberculosis patients infected with the HIV? Am Rev Respir Dis (1987) 0.91
Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Pharmacotherapy (1994) 0.90
Susceptibility of beige mice to Mycobacterium avium complex infections by different routes of challenge. Am Rev Respir Dis (1989) 0.87
Levofloxacin for drug-resistant Mycobacterium tuberculosis. Ann Pharmacother (1998) 0.87
Tuberculosis in the elderly: treating the "white plague". Geriatrics (1980) 0.85
If a tree falls in the middle of the forest. Isoniazid and hepatitis. Am Rev Respir Dis (1989) 0.84
Interstitial pneumonia in angio-immunoblastic lymphadenopathy with dysproteinemia. A case report with special histopathologic studies. Ann Intern Med (1976) 0.83
Compliance and tuberculosis treatment. Lancet (1991) 0.82
Treatment and prevention of multidrug-resistant tuberculosis. Res Microbiol (1993) 0.82
Tuberculous pleural effusions developing during chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1974) 0.82
Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med (1990) 0.82
Synergism: the Rosetta stone for Mycobacterium avium complex chemotherapy? Am Rev Respir Dis (1988) 0.82
AIDS and TB drug absorption. Int J Tuberc Lung Dis (1999) 0.80
Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control. Tuber Lung Dis (1996) 0.79
Treatment of tuberculosis in alcoholic patients. Am Rev Respir Dis (1977) 0.78
Resection of the right middle lobe and lingula for mycobacterial infection. Ann Thorac Surg (1996) 0.78
Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy (1997) 0.76
What's in a name ... TB or not TB? Tuber Lung Dis (1996) 0.75
"Koch's lymph" 107 years later--an oldie but not a goldie. Clin Infect Dis (1997) 0.75
Tuberculosis chemotherapy: do it right the first time. South Med J (1999) 0.75
Severe recurrent Crohn's disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial) therapy. Gut (2006) 0.75
Leap-frogging technology into the next century: better diagnostic tests for TB. Int J Tuberc Lung Dis (1998) 0.75
Tuberculosis in young adults and the elderly. Chest (1995) 0.75
Multidrug-resistant tuberculosis. N Engl J Med (1992) 0.75
Tuberculosis control strategies and utilitarianism. Int J Tuberc Lung Dis (2000) 0.75
Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome. Antimicrob Agents Chemother (1987) 0.75